Has Felix Cheung, MD received payments from drug or device companies?

Yes. Drug and device makers reported $9,547 in general payments to Felix Cheung, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Felix Cheung, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Felix Cheung, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Felix Cheung, MD

Urology · New York, NYNPI 1184913527

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Boston Scientific at 38.9% of the total. Reporting peaked in 2022 at $2,703 and has fallen 68.4% since, to $854 in 2025.

$9,547in general payments, 2019–2025

Across 79 payments — averaging $120.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$4K
Procept Biorobotics Corporation$4K
Axonics, Inc.$1K
Medtronic$197
Profound Medical Corp.$172
Ferring Pharmaceuticals Inc.$155
plus $306 from 3 others

$17,330in research payments, 2019–2025

Across 1 payment — averaging $17,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Provepharm Inc.$17K

What the payments were for

Travel & lodging$4,27345%
Food & beverage$5,27455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	32	$3,713
Procept Biorobotics Corporation	28	$3,659
Axonics, Inc.	13	$1,345
Medtronic	1	$197
Profound Medical Corp.	1	$172
Ferring Pharmaceuticals Inc.	1	$155
Olympus America Inc.	1	$143
Innovation Technologies Inc	1	$127
Valencia Technologies Corporation	1	$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AquaBeam Robotic System$2,843
Axonics r-SNM System$942
Bulkamid$792
GENERAL - THERAPIES$722
GENERAL KIDNEY STONE DISEASE$359
SOLYX$262
INTERSTIM$197
Tulsa-Pro$172
ADSTILADRIN$155
AQUABEAM SYSTEM$144
iTIND System$143
TACTRA$143
AMS 800 Artificial Urinary Sphincter$132
Irrisept$127
ADVANTAGE FIT$123
Solyx SIS System$120
LITHOCLAST$119
GENERAL BPH$113
GENERAL ERECTILE DYSFUNCTION$109

How this compares

$9,547 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024

$192,277

Medicare patients

730

Services billed

1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	220	$149,632
GemtesaVibegron	57	$37,091
Solifenacin Succinate	118	$12,611
Mirabegron ErMirabegron	15	$9,023
Tamsulosin Hcl	301	$5,151
Fesoterodine Fumarate ErFesoterodine Fumarate	17	$2,112
Silodosin	24	$2,086
Tolterodine Tartrate ErTolterodine Tartrate	15	$1,781
Oxybutynin Chloride ErOxybutynin Chloride	61	$1,476
Estradiol	18	$1,257
Alfuzosin Hcl ErAlfuzosin Hcl	11	$553
Finasteride	34	$515
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	83	$494
Trospium Chloride	17	$467
Cefdinir	28	$410

Paid to pharmacies, not to this prescriber.

Other urology in New York

Bilal ChughtaiNew York$658K
Katie MurrayNew York$575K
Neil BanderNew York$544K
Robert ValenzuelaNew York$494K
Kyrollis AttallaNew York$381K
Benjamin BruckerNew York$364K
Ketan BadaniNew York$285K
Michael GrassoNew York$284K
Mantu GuptaNew York$229K
Robin SmithNew York$215K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →